摘要
目的探讨粗针穿刺活检及新辅助化疗对于乳腺肿瘤ER/PR/PS2/HER-2免疫组化结果的影响。方法乳腺粗针穿刺活检,病理诊断为乳腺癌并UICC分期,所有患者采用CEF或TE方案化疗,分别接受了2个周期及3～4周期的新辅助化疗。同时将穿刺的组织行ER、PR、PS2和HER-2免疫组化的测定,进行对比分析。结果新辅助化疗FAC或TE两种不同化疗方法治疗48例乳腺癌,FAC法化疗26例,占54.2%,TE法化疗22例,占45.8%。乳腺癌新辅助化疗前、后乳腺粗针穿刺活检,免疫组化检测结果ER/PR/PS2/HER-2阳性率无明显增加。结论新辅助化疗对乳腺癌粗针穿刺活检免疫组化ER/PR/PS2/HER-2的表达无显著影响。
Objective To explore the core needle biopsy and neoadjuvant chemotherapy for breast cancer ER/PR/PS2/HER-2 immunohistochemical outcomes.Methods Breast core needle biopsy and pathological diagnosis of breast cancer and the UICC stage,all patients received chemotherapy with CEF or TE,respectively,received 2 cycles and 3 to 4 cycles of neoadjuvant chemotherapy.Puncture while the tissues were ER,PR,PS2,and HER-2 immunohistochemical determination of comparative analysis.Results Neoadjuvant chemotherapy FAC or TE in two different chemotherapy treatment of 48 cases of breast cancer,FAC chemotherapy in 26 cases accounted for 54.2%,TE accounted for 45.8% of chemotherapy in 22 cases.Neo-adjuvant chemotherapy of breast cancer before and after breast core needle biopsy and immunohistochemistry test results ER/PR/ PS2/HER-2 positive rate was not significantly increased.Conclusion Neoadjuvant chemotherapy for breast cancer before and after core needle biopsy immunohistochemical ER/PR/PS2/HER-2 expression had no significant effect.
出处
《医药论坛杂志》
2010年第6期43-44,47,共3页
Journal of Medical Forum
关键词
粗针穿刺活检
乳腺癌
新辅助化疗
免疫组化
Core needle biopsy
Breast cancer
Neo-adjuvant chemotherapy
Immunohistochemistry
